The contract also provides Eisai with a choice to jointly develop and commercialize two of Biogen Idec's applicants for Advertisement, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody. Corporate and Commercial Actions In January 2014, Biogen Idec and UCB announced they have signed exceptional agreements granting UCB the proper to commercialize Biogen Idec items in South Korea, Hong Kong, Thailand, Singapore, Taiwan and Malaysia, also to develop and commercialize Biogen Idec items in China. February 2014 In, Biogen Idec announced that Chairman of the Plank William D. Small will retire from the Firm's Plank of Directors, able to the ongoing company;s 2014 annual conference of stockholders. Mr.These positive medical results, achieved with our house dirt mite allergy treatment, are particularly encouraging as they mirror those from earlier successful studies with this cat and ragweed allergy therapies, stated Steve Harris, Circassia’s CEO. Our rapidly growing clinical database clearly demonstrates the potential of Circassia’s T-cell vaccines to significantly improve allergy treatment, by giving sufferers a convenient and well tolerated alternative to existing immunotherapies. We have made significant progress in advancing a number of allergy T-cell vaccines into mid – to late-stage development, and we continue steadily to work hard to provide these innovative therapies to advertise as fast as possible.